Canaccord lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $9 and keeps a Hold rating on the shares. The firm said they reported its 4Q24 results after the close and Zurzuvae (zuranolone for post-partum depression/PPD) collaboration revenue came in at $11.4M versus our $12.1M estimate and consensus of $13.7M. Canaccord said they will continue to keep a close watch on Zurzuvae’s performance given partner Biogen’s (BIIB) unsolicited takeover approach, which Sage has decided not to accept, and Sage’s ongoing strategic review.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration
- Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties
- Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright
- Sage Therapeutics Reports Strong 2024 Performance
- SAGE Therapeutics: Hold Rating Amid Financial Challenges and Uncertain Outlook